For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...
Histological analysis of the resected specimen diagnosed a Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) with mild lymphocytic submucosal inflammation. Crucially, there was no ...
The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...
The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback